Kimal launch Celt ACD

At the recent PCR meeting in Paris, Kimal launched the innovative Celt ACD®, a revolutionary approach to femoral artery closure.

Delegates were excited to see this novel new product which offers numerous advantages over alternatives currently available.

Providing almost immediate haemostasis, the Celt ACD® is easy to learn to use as there are only three steps to deployment.

The Celt ACD® is now CE Marked and undergoing FDA trials in the US .